Eight Roads Ventures-backed Adcentrx Therapeutics has raised more Series A funds, while Chinese VC firm Vision Plus Capital has invested in the Canadian food delivery platform Fantuan.
Adcentrx Therapeutics raises another $13m
Adcentrx Therapeutics, a San Diego-based biopharmaceutical firm developing Antibody-Drug Conjugate (ADC) therapeutics for cancer, has bagged another $13 million from new investors.
Shanghai-based, life science-focused venture capital firm Quan Capital; and Seoul-based investment firm Partners Investment are among the new investors that participated in the capital injection.
The fresh $13 million investment has brought the total capital raised in the extended Series A round to $51 million, according to a release shared by Fidelity-backed global venture capital firm Eight Roads Ventures which led Adcentrx Therapeutics’ extended Series A round in April.
Founded in 2021, Adcentrx Therapeutics aims to advance at least one candidate into the clinical stage each year. The company’s lead candidate—ADRX-0706—is expected to enter a first-in-human Phase 1 clinical trial in the second half of 2023, per the company.
Vision Plus Capital joins Fantuan’s Series C round
Canada-based food delivery platform Fantuan has secured $40 million in a Series C financing round co-led by US investment Celtic House Asia which invests in early-stage consumer marketplaces and digital health firms across North America and China.
San Francisco-based food technology company GrubMarket also led the investment; while Irvine, California-based private equity firm JSD Capital and Hangzhou-based Vision Plus Capital are the participating investors.
Founded in 2014, Fantuan operates a one-stop platform encompassing food and grocery delivery across Canada, the United States, Australia, and the UK.
Previously, the firm sealed its $35-million Series B round in January 2021 led by Chinese PE firm Orchid Asia.